en.Wedoany.com Reported - A study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois, USA, found that women using menopausal hormone therapy have a lower risk of developing low bone density compared to non-users. The study included 387 postmenopausal women who underwent DXA scans between 2021 and 2025, of whom 33% were users of menopausal hormone therapy and 67% were non-users. Low bone density was defined as osteopenia or osteoporosis.

Compared to non-users, women using menopausal hormone therapy had approximately a 69% lower risk of low bone density in the spine and hip. This association remained significant after adjusting for age, time since menopause, vitamin D levels, smoking, and other health conditions.

The study was led by Diego Espinoza-Peralta, M.D., M.Sc., Vice President of the Mexican Society of Nutrition and Endocrinology (SMNE) and Principal Investigator at Investigación Médica Sonora (INMEDS). He noted that for years, many women have avoided menopausal hormone therapy due to safety concerns and warning labels. This study reexamines that perspective, suggesting that menopausal hormone therapy may have additional benefits for bone health, helping to alleviate menopausal symptoms and prevent bone loss or reduce fracture risk.

Espinoza-Peralta stated that clinicians may more carefully weigh its benefits, especially in early postmenopausal women, which could improve long-term health and quality of life.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com